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Abstract 
 
Huntington Disease (HD) is a progressive neurodegenerative disorder characterized 
by the loss of cognition and motor ability.  Beginning in the dysfunction of the 
GABAergic neurons, HD has been mainly attributed to an increased number of CAG 
repeats in the Huntingtin gene, resulting in an extended polyglutamine tract within the 
protein. This expansion prevents the normal interaction between the proteins encoded by 
Htt and Huntingtin interacting protein 1 (Hip1). Conserved sequences between human 
and Drosophila Hip1 allow examination of the protein in D. melanogaster to be used as a 
model for human HD. Analysis of the loss of function of Hip1 in a pan-neuronal fashion 
resulted in an increase in average lifespan and decrease in motor ability. Overexpression 
of Hip1 resulted in a decrease in both lifespan and motor ability, suggesting a delicate 
balance of Hip1 in healthy cells. Investigation of the biological effects of altered Hip1 
expression may provide insights into a possible role for Hip1 in HD pathogenesis.  
The progression of Parkinson Disease (PD) is similar to that of HD – generally 
occurring later in life, and affecting cognitive ability and motor function. Associated with 
the death of dopamingeric neurons, impairment of a number of genes has been implicated 
in disease progression. Recently, a polymorphism in Huntingtin interacting protein 1 
Related (Hip1R), was identified as a risk-factor for PD. The Hip1R gene is not found in 
D. melanogaster, but is considered an orthologue of Hip1, which is conserved across 
species. Directed manipulation of the single Drosophila Hip1 in the dopaminergic 
neurons was carried out to provide an in vivo model of disease progression and symptom 
development. Investigation of motor ability and longevity of D. melanogaster upon 
overexpression and loss of function of Hip1 was completed. Loss of expression of Hip1 
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in the dopaminergic neurons, through the use of RNAi, decreased the locomotor ability of 
the flies and increased the average lifespan. Overexpression of Hip1 in the dopaminergic 
neurons revealed the opposite effect, improving locomotor ability and slightly decreasing 
average lifespan. This suggests that a delicate balance of Hip1 exists in the dopaminergic 
neurons, and alteration of expression affects the motor ability and life expectancy. 
Maintaining a healthy balance of Hip1 in the dopaminergic neurons may offer a new 
therapeutic option for loss of locomotor ability and pre-mature death. Further 
investigation of Hip1R and its role in human disease progression is needed, and may be 
crucial to our understanding of PD in order to provide new therapeutic targets. 
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Chapter 1 - Introduction and Overview 
 
1.1. Neurodegenerative Disease 
A neurodegenerative disease is defined as a chronic condition that is caused by the 
deterioration or degradation of neuronal tissues over time (1). Advances in medical 
science have increased both the average lifespan and the quality of life. Unfortunately, 
this leads to a rise in the incidence of diseases that begin later in life including 
neurodegenerative diseases such as Huntington Disease (HD), Parkinson Disease (PD) 
and Alzheimer Disease (AD). The progression of neurodegenerative disease was 
originally believed to depend upon environmental factors (2). Advances in genomic and 
proteomic technologies, such as microarrays, RNA-Seq and Next-Gen sequencing have 
revealed a number of new genes, along with novel functions for genes previously thought 
to be “junk” or non-functional. The discovery of common genetic risk loci between 
patients with the same neurodegenerative disorder and heritability patterns suggests 
instead that genetic factors may be the major contributors to disease development and 
progression (3). Mutations found in the TMEM230 gene, for example, have recently been 
implicated in PD pathogenesis (4). This creates a need to better understand the etiology 
behind these diseases. The genetic background of Huntington Disease and Parkinson 
Disease has been partially characterized, but many of the molecular mechanisms and 
cellular pathways are still largely unknown (5). An investigation into the genes involved 
in these diseases and the role they play in the cell can increase our understanding of 
disease pathogenesis and potentially provide novel therapeutic targets and treatment 
options.  
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1.1.1. Huntington Disease 
Huntington Disease is a progressive neurodegenerative disorder that affects between 4 
and 8 people in 100,000, displaying its highest prevalence in Europe and North America 
(6, 7). Discovered by George Huntington in 1872, HD is inherited in an autosomal 
dominant fashion, and on-set of disease typically occurs in mid-late life, although juvenile 
forms of HD do exist. Symptoms of HD include impaired cognition, loss of motor ability, 
dementia, involuntary convulsive movements, severe weight loss, saccadic eye 
movements and changes in sleeping patterns, with the end result often being premature 
death (7, 8). Current treatments and therapeutic agents aid in reducing severity of 
symptoms but do not address the underlying cause of disease.   
Beginning in the spiny GABAergic neurons of the striatum and deep layers of the 
cortex, neuronal death spreads as the disease progresses (6). Upon reaching the 
hypothalamus and hippocampus, the sufferer’s body begins to shut down major organ 
function, resulting in death (9). HD occurs in patients which exhibit an expanded number 
of CAG repeats in exon 1 of the Huntingtin (Htt) gene, found on the short arm of 
chromosome 4 (10). This results in an increased number of glutamine residues in the 
Huntingtin protein. Beginning at the 18th amino acid, the polyQ domain is present in 
healthy individuals, but contains only 11 to 34 glutamine residues. In general, patients 
with 37 or more glutamine residues are diagnosed with HD (9). The number of CAG 
repeats present in disease patients is proportional to disease severity and inversely 
proportional to age of onset (10). Expansion of the Htt protein influences structure and 
functionality, rendering the protein unable to interact with a number of its normal binding 
partners (9). While disease symptoms are generally contributed to the mutation of Htt, it 
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is highly probable that many of the symptoms may be the result of the dysfunctional 
complexes and downstream cellular pathways.  
1.1.2. Hip1 in Huntington Disease 
Huntingtin is expressed in a wide variety of tissues and thus the normal functions of 
the protein have been difficult to characterize. The Huntingtin protein has a number of 
binding partners, including proteins involved in metabolism, cellular signalling and 
trafficking, endocytosis and transcription (9). Therefore, disruptions in the proteins’ 
normal binding patterns (such as in HD) can alter cellular pathways, and may contribute 
to the etiology of Huntington Disease.  
One binding partner of Htt, Huntingtin interacting protein 1 (Hip1), binds to the 
region of the protein that contains amino acids 1-540, and exhibits reduced affinity upon 
polyQ expansion. Normally involved in trafficking, endocytosis, neurogenesis and 
apoptosis, Hip1 is left in a ‘less-bound’ state in the cytoplasm when in the presence of 
expanded Htt. Not only unable to complete its standard cellular functions, when Htt does 
not bind Hip1 as it normally does, Hip1 can be sequestered by other proteins to form 
aggregates, which may provide the potential for disease phenotypes (9, 11-14). Hip1 is 
highly conserved throughout evolutionary history (14), and so an overexpression of Hip1 
in D. melanogaster is expected to mimic aspects of the effects of Hip1 in HD patients by 
increasing the amount of unbound Hip1 in the cytoplasm, and providing the opportunity 
for aggregation. Investigating the effects of altered Hip1 expression in the fruit fly is 
expected to provide insights into the pathology of HD in humans.  
Huntingtin interacting protein 1 protein interactor (Hippi) (also known as Che-13) is a 
novel protein that as the name suggests, binds to Hip1 in healthy individuals. A positive 
	 1-4	
correlation was found between Hip1 and Hippi expression in humans (11). One promising 
model for HD was proposed based on the Hip1-Hippi interaction, suggesting that when 
the affinity of Hip1 for Htt is lost due to the polyQ expansion, the free Hip1 binds Hippi 
instead. This complex not only causes the formation of aggregates, it activates pro-
caspase-8, presumably initiating apoptosis (11). Therefore, an investigation of altered 
Hippi expression could contribute to the working knowledge of HD pathogenesis.  
1.1.3. Parkinson Disease 
Parkinson Disease (PD) is one of the most prevalent progressive neurodegenerative 
disorders known to date, second only to Alzheimer Disease (15). Affecting 1% of the 
population above the age of 65 and 4 to 5% of the population above 85 years of age, PD 
is characterized by the loss of cognitive ability and motor function (16, 17). Initially 
believed to be the result of environmental factors including brain trauma and chemical 
exposure, recent advances suggest a significant role of genetic causation (3, 18). The 
sequencing of the human genome opened up new possibilities, and efforts were focused 
on finding potential risk factors – mutations that may make a patient more susceptible to 
disease onset in accordance with environmental factors (19). Beginning in the 
Dopaminergic neurons of the substantia nigra, neuronal death spreads as the disease 
progresses (17). No single cellular dysfunction has been isolated as the cause of PD, but a 
number of genes have been implicated as having roles in disease pathogenesis. Mutations 
in Pink1, parkin, PGC-1α, PARIS and α-synuclein have all been linked to disease 
progression (5, 20-23). Understanding the cellular components and molecular pathways 
involved in PD may provide novel treatment options and therapeutic targets. 
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1.1.4. Hip1R in Parkinson Disease 
Recently, a polymorphism in Huntingtin interacting protein 1 Related (Hip1R) was 
identified as a risk factor for PD in a genome wide association study (24, 25). Considered 
an orthologue of Hip1, Hip1R shares similar domains and structure but is involved in 
somewhat different cellular functions (26, 27). Although originally believed to form 
heterodimers, recent evidence suggests that the Hip1 and Hip1R proteins preferentially 
form homodimers in vivo, interacting through the flexible coiled coil domains found in 
both proteins. The flexibility observed in the coiled coil domain may contribute to the 
proteins ability to interact with a number of binding partners including Hippi, Htt and the 
clathrin light chain (27-31). As the implication of Hip1R in PD is still a novel idea, the 
role of Hip1R in PD is mainly uncharacterized. Conformational changes resulting in 
Hip1R interacting with novel binding partners provides a good theory on which to base 
the investigation of the role of Hip1R in the pathogenesis of PD.  
1.1.5. Drosophila melanogaster as a model of neurodegenerative disease 
The common fruit fly, Drosophila melanogaster has been used to model many 
human diseases. Having a short generation time and numerous progeny, culturing and 
maintaining D. melanogaster in the laboratory is relatively simple and is much less 
expensive than maintaining other organisms (32). The D. melanogaster genome was 
sequenced in the year 2000, and it revealed that about 75% of disease related genes in 
humans have Drosophila counterparts (32). Although simpler than the human nervous 
system, D. melanogaster boasts a compartmentalized nervous system that can be 
genetically manipulated with relative ease (33-35). Forward and reverse genetic screens 
can be used to identify new genes and their functions, while the UAS-Gal4 bipartite 
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ectopic expression system allows different genes to be over expressed or knocked down 
in a variety of tissues (33). Based on the Gal4 transcription factor found in yeast 
(Saccharomyces cerevisiae), Gal4 binds to the Upstream activating sequence (UAS), 
driving gene expression. Transgenic organisms formed by insertion of the UAS upstream 
of the target gene and random insertion of Gal4 in opposite parental lines can then be 
mated, providing accurate and precise control of gene expression (35) (Figure 1.1). 
Combined with the use of RNA interference (RNAi), a sequence-specific gene silencing 
mechanism (36), the UAS-Gal4 system offers the tools to easily manipulate the 
Drosophila genome, providing a platform on which to base the study of human disease. 
Bioinformatic analysis revealed that the closest D. melanogaster homologue for both 
human Hip1 and Hip1R is Drosophila Hip1 (Figure 1.2). As the two proteins perform 
different functions but display evolutionary similarity, it is possible that alternative 
splicing of Hip1 in D. melanogaster could produce alternate versions of the proteins that 
perform different functions. Alternative first exons produce Hip1 and HipDANTH, and 
thus it is possible that other isoforms of the protein exists (14). While no direct evidence 
for this model exists for Hip1, other genes, such as the Drosophila Hox gene 
Ultrabithorax (Ubx) are known to generate different isoforms that perform different 
functions through alternative splicing (37-40). Thus, an investigation of altered Hip1 
expression on D. melanogaster lifespan and locomotor ability may provide insight into 
both Huntington Disease and Parkinson Disease.  
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Figure 1.1 - The UAS-Gal4 expression system in D. melanogaster. Maternal UAS lines 
crossed to paternal Gal4 lines produce progeny in which expression of the target gene 
occurs through binding of the Gal4 protein to the UAS sequence. Parental lines carry only 
UAS or Gal4, and, therefore, are viable, fertile and healthy and can be maintained through 
the standard procedures of Drosophila culture. The use of RNAi transgenes provides the 
ability to examine loss of function.    
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Figure 1.2 - Hip1 and Hip1R share similar domains across species. Conservation of the 
ANTH and talin-like (I/LWEQ) domains of D. melanogaster and human Hip1 suggest 
similar functions for the protein throughout evolutionary history. The ANTH domain is 
also conserved in human Hip1R, and the protein itself shows a high degree of 
conservation, suggesting that Hip1R is paralogous to Hip1.  
A. Visual depiction of proteins.   
B. Partial alignment of the ANTH domain from D. melanogaster Hip1, Human Hip1 and 
Human Hip1R in that order. An asterisk (*) indicates amino acids that are fully 
conserved, A colon (:) indicates conservation between groups of strongly similar 
properties (>0.5 in the Gonnet PAM 250 matrix), A period (.) indicates conservation 
between weakly similar properties (<0.5 in the Gonnet PAM 250 matrix).  
Refer to appendix A for supplemental data.  
  
ANTH% I/LWEQ%
H.#sapiens#Hip1%
H.#sapiens#Hip1R%
D.#melanogaster#Hip1% 1124%
1030%
603%
A"
B"
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1.2. Research goals 
While Hip1 and Hip1R have been suggested as candidate genes in the development of 
neurodegenerative disease, their role in disease progression and onset has not been fully 
characterized. This project aims to examine the effects of overexpression and inhibition 
of Hip1 and Hippi in a pan-neuronal fashion and specifically in the dopaminergic neurons 
of D. melanogaster. Examining the effects of altered gene expression on D. melanogaster 
lifespan and motor ability may establish a role for Hip1 and Hip1R in the pathogenesis of 
HD and PD respectively and suggest that Hip1 and Hip1R dysfunction contribute to 
disease phenotypes. It also aims to expand upon the working knowledge of the Hippi 
protein, and its role in disease pathogenesis.   
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Chapter 2 - Modelling Huntington Disease through Huntingtin interacting protein 1 
in Drosophila melanogaster 
 
2.1  Introduction 
Huntington Disease (HD) is a progressive neurodegenerative disorder, with symptoms  
varying from loss of cognition and motor control to weight loss and changes in sleeping 
patterns, generally ending in premature death (7). HD occurs upon expansion of a CAG 
repeat in the Huntingtin (Htt) gene, resulting in an expanded polyglutamine tract of the 
protein (10). The number of polyglutamine residues present displays a positive correlation 
with disease severity and a negative correlation with age of onset (9, 10).  The increased 
number of polyglutamine residues has a drastic impact on the cell – effecting protein 
folding, binding ability and causing aggregate formation, eventually leading to the 
selective death of neurons in the brain (6, 9). Upon expansion, Htt is unable to bind to a 
number of its normal binding partners, including Huntingtin interacting protein 1 (Hip1), 
which is then left unbound in the cytoplasm with the potential to be sequestered by other 
proteins and then to form aggregates (9). The symptoms of HD were originally 
contributed to the expansion in the polyglutamine tract of Htt.  However, it is probable 
that several Htt binding partners contribute to disease symptoms and pathogenesis. 
Involved in trafficking, endocytosis, apoptotic cell signalling and neurogenesis (9, 11-14, 
41), a disruption in the interaction between Htt and Hip1 could have detrimental effects 
within the cell.  
The Hip1 gene has been highly conserved throughout evolutionary history. A 
comparison of human and D. melanogaster Hip1 proteins reveals three highly conserved 
domains; the N-terminal lipid binding ANTH domain, a coiled coil and a C-terminal 
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talin-like I/LWEQ domain (14, 28). The degree of evolutionary conservation suggests a 
highly conserved function and thus an investigation of the effects of altered Hip1 
expression in D. melanogaster may provide insights into the pathology of HD human 
patients. In this study, increased and reduced Hip1 expression in D. melanogaster is used 
to mimic the same conditions in humans, to examine the effects on lifespan and 
locomotor ability.  
2.2  Materials and Methods 
2.2.1 Drosophila melanogaster stocks and culture 
The UAS-lacZ responder line (42), UAS-GFP responder line (43), UAS-Hip1-
RNAi32504 responder line (44) along with the elav-Gal4 (45) and GawBl(3)31-1 (46) 
transgenic lines were obtained from the Bloomington Drosophila Stock Center 
(University of Indiana, Bloomington, USA). The UAS-Hip1L2, UAS-HipL6 and UAS-
Hip1S11.2 (ΔANTH) transgenic lines were generated by our research group by Justin 
Moores (14). The UAS-Hip1-RNAi106978 (47, 48) was obtained from the Vienna 
Drosophila Resource Center (Vienna Biocenter, Vienna, USA). The w1118 stock was 
generously provided by Dr. Howard Lipshitz, of the University of Toronto (Toronto, 
Canada). The expression patterns of fly lines used in this analysis and the place of 
insertion can be found in Table 1. 
D. melanogaster were cultured on standard media composed of 65 g/L cornmeal, 10 
g/L yeast, 5.5 g/L agar and 50 ml/L fancy grade molasses in water supplemented with 5 
ml of 0.1 g/mL methyl paraben in 95% ethanol and 2.5 mL of propionic acid. All 
experiments were at 25° C. 
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Crosses were set up by placing three to five UAS-bearing virgin females of the 
corresponding genotype and two to five Gal4-bearing males together on standard media. 
To increase the number of progeny, parental flies were placed on new media at day 2, 4 
and 6 post experimental initiation. Critical class males were selected. 
Table 2.1 – Genotypes, location of transgene insertion and expression patterns used in the 
analysis of Hip1 overexpression and the loss of function of Hip1 expressed in a pan-
neuronal fashion to determine their role in the pathogenesis of Huntington Disease.  
Genotype Insertion 
Chromosome 
Affected 
Chromosome 
Expression Patterns 
w1118 N/A 1 N/A 
UAS-lacZ 2 1;2 Expresses lacZ under UAS control 
UAS-GFP 3 3 Expresses GFP under UAS 
control 
UAS-Hip1-
RNAi106978 
2 1;2 Expresses dsRNAi for Hip1 under 
UAS control 
UAS-Hip1-
RNA132504 
3 1;3 Expresses dsRNAi for Hip1 under 
UAS control 
UAS-Hip1L2 Unknown Unknown Expresses Hip1 under UAS 
control 
UAS-Hip1L6 Unknown Unknown Expresses Hip1 under UAS 
control 
UAS-Hip1S11.2 Unknown Unknown Expresses Hip1DANTH under 
UAS control 
elav-Gal4 1 1 Gal4 expressed in all tissues of 
the embryonic nervous system 
beginning at stage 12 
GawBl(3)31-1 3 1;3 Gal4 expressed in neuroblasts and 
neurons 
 
2.2.2 Longevity assay 
Critical class male progeny were isolated on the day of eclosure and maintained at 
25°C on standard media in vials of 23 or less. Flies were scored every two days for the 
presence of deceased individuals, and provided with fresh media regularly to ensure ideal 
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conditions (N ³ 269). Data was analyzed using GraphPad Prism 5.0c or 7.0b (GraphPad 
Software, Inc., San Diego, California, USA), survival curves were generated and a 
Mantel-Cox test was performed to determine significance; indicated by a P value of less 
than 0.05. 
2.2.3 Locomotor assay 
Critical class male progeny were isolated on the day of eclosure and maintained at 
25°C on standard media in vials of 10 or less. Beginning at day 2 post eclosion, and at 
regular seven day intervals afterward, flies were scored for climbing ability. In glass 
tubes, flies were given 10 seconds to climb, and then the maximum level that they 
reached was recorded (20). A climbing index was calculated to determine climbing 
ability, using the formula described below:  
Climbing Index = (nm/N) 
where n=number of flies at level, m=score for the level and N=total number of flies 
climbed (49). 
A cohort of 50 or less individuals from each genotype were analyzed in groups of 10 
or less (N = 50). Each cohort underwent a total of 10 trials, providing a total trial number 
of 500 flies per genotype per session. This analysis was continued until less than 10 flies 
remained alive or flies received a minimum score for two consecutive sessions. A 
climbing curve (non-linear regression curve) was generated using GraphPad Prism 5.0c or 
7.0b software (GraphPad Software, Inc., San Diego, California, USA). A comparison of 
fits of the non-linear regression curves taking the Y-intercept (initial climbing ability) and 
	 2-5	
slope (rate of decline in climbing ability) into consideration concluded if the curves were 
significantly different, indicated by a P value less than 0.05. 
2.3 Results 
Examination of altered Hip1 expression in a pan-neuronal fashion can provide 
insights into the role of Hip1 in neurodegenerative diseases such as Huntington Disease, 
and determine the effects on disease phenotypes. Investigation with elav-Gal4 revealed 
decreased lifespan with UAS-GFP (LD50 = 52) compared to UAS-lacZ (LD50 = 70) and 
w1118 (LD50 = 70) (Figure 2.1a). Both UAS-GFP and w1118 displayed a reduction in motor 
function compared to UAS-lacZ (Figure 2.1b). Due to the nature of the control 
phenotypes, UAS-lacZ served as an appropriate control for this analysis.  
An investigation of loss of function of Hip1 revealed an increase in average lifespan 
with elav-Gal4; UAS-Hip1-RNAi106978 displaying a median lifespan of 78 days compared 
to 70 days for the elav-Gal4; UAS-lacZ control (Figure 2.1c). The elav-Gal4; UAS-Hip1-
RNAi32504 males had a median lifespan of 70 days, showing no significant difference 
compared to the UAS-lacZ control. Both elav-Gal4; UAS-Hip1-RNAi106978 and elav-Gal4; 
UAS-Hip1-RNAi32504 showed a significant loss in motor ability (Figure 2.1d). 
Overexpression of Hip1 by elav-Gal4 has the opposite effect, decreasing median lifespan 
to 60 days with elav-Gal4; UAS-Hip1L2 and 54 days with elav-Gal4; UAS-Hip1L6, along 
with a clear premature loss of climbing ability (Figure 2.1e, f). Overexpression of 
truncated Hip1 in elav-Gal4; UAS-Hip1DANTHS11.2 further reduced climbing ability 
(Figure 2.1f) but had no significant effect on median lifespan (Figure 2.1e), to suggest 
that the lipid binding domain may play a significant role in motor function.  
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Figure 2.1 - Altered expression of Hip1 through the elav-Gal4 transgene affects longevity 
and motor function. A, C and E: Longevity assay of Drosophila melanogaster males 
displaying altered Hip1 expression in a pan-neuronal fashion. Longevity is shown as percent 
survival (P < 0.05, determined by log rank). The dotted line represents median survival of 
flies. Error bars represent standard error of the mean (N³295). B, D and F: Locomotor assay 
of D. melanogaster males displaying altered Hip1 expression in a pan-neuronal fashion. 
Climbing ability was determined via nonlinear curve fit (CI=95%).  Error bars indicate 
standard error of the mean, N = 50. Genotypes are as follows: elav-Gal4; + (w1118), elav-
Gal4; UAS-lacZ, elav-Gal4; UAS-GFP, elav-Gal4; UAS-Hip1-RNAi106978, elav-Gal4; UAS-
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Hip1-RNAi32504, elav-Gal4; UAS-Hip1L2, elav-Gal4; UAS-Hip1L6, elav-Gal4; UAS-
Hip1DANTHS11.2. See Appendix B for supplemental data. 
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A similar analysis completed using GawBl(3)31-1 revealed no significant difference in 
lifespan between no responder GawBl(3)3-1; + (LD50 = 52), GawBl(3)3-1; UAS-lacZ (LD50 
= 58) and UAS-GFP (LD50 = 52) (Figure 2.2a), although GawBl(3)3-1; + did display a 
significant increase in locomotor function (Figure 2.2b). Upon a comparison of GawBl(3)3-
1;UAS-lacZ with GawBl(3)31-1; UAS-Hip1-RNAi106978, GawBl(3)31-1; UAS-Hip1L2, 
GawBl(3)31-1; UAS-Hip1L6, GawBl(3)31-1; UAS-Hip1DANTHS11.2, no significant difference 
was found in survival or motor function, with median lifespans of 46, 56 and 52 
respectively (Figure 2.2c, d, e & f). GawBl(3)31-1; UAS-Hip1-RNAi32504 did display a 
decrease in motor function, but no change in average lifespan (LD50 = 55). A slight 
increase in average lifespan (LD50 = 58) and motor ability was observed upon 
Hip1DANTH overexpression (Figure 2.2e & f). It is plausible that the GawB line may not 
direct expression as powerfully as other Gal4 lines, and that this may affect the results 
shown here.   
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Figure 2.2 - Altered expression of Hip1 through the GawBl(3)3-1 -Gal4 transgene affects 
longevity and motor function. A, C and E: Longevity assay of Drosophila melanogaster 
males displaying altered Hip1 expression in a pan-neuronal fashion. Longevity is shown as 
percent survival (P < 0.05, determined by log rank). The dotted line represents median 
survival of flies. Error bars represent standard error of the mean (N³269). B, D and F: 
Locomotor assay of D. melanogaster males displaying altered Hip1 expression in a pan-
neuronal fashion. Climbing ability was determined via nonlinear curve fit (CI=95%).  Error 
bars indicate standard error of the mean, N = 50. Genotypes are as follows: GawBl(3)31-1; + 
(w1118), GawBl(3)3-1; UAS-lacZ, GawBl(3)31-1; UAS-GFP, GawBl(3)31-1; UAS-Hip1-RNAi106978, 
GawBl(3)31-1; UAS-Hip1-RNAi32504, GawBl(3)31-1; UAS-Hip1L2, GawBl(3)31-1; UAS-Hip1L6, 
GawBl(3)31-1; UAS-Hip1DANTHS11.2. See Appendix C for supplemental data.  
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2.4 Discussion 
Alteration of the cellular expression levels of Hip1 effected whole organism 
longevity and some aspects of neuronal development – particularly growth. Flies 
expressing an increased amount of Hip1 display a reduction in average lifespan and a 
reduction in motor function over time (Figure 2.1e & f). This reduction in lifespan 
indicates that Hip1 may be involved in cellular pathways related to cellular and whole 
organism survival and death. Previously implicated in the induction of apoptosis, Hip1 
activates caspase-8 upon the formation of a complex with Hippi. (11). In HD, Hip1 
cannot bind the mutated Htt and thus the unbound levels in the cell increase, leaving it 
free to create other complexes such as the Hip1-Hippi heterodimer (9, 11). The 
overexpression of Hip1 experimental line was designed to mimic the suggested HD 
pathology in this way, and thus the reduction in lifespan and motor ability provides a 
promising model of neurodegenerative disease. 
Overexpression of Hip1DANTH did not result in the reduction in lifespan observed 
with the overexpression of full length Hip1 (Figure 2.1e). The loss of the lipid binding 
domain occurs naturally upon the expression of alternative first exons, and likely causes 
conformational changes in the protein, influencing folding and protein binding ability and 
rendering it less able to interact with its normal binding partners (14). The reduced ability 
to bind to Hippi and activate Caspase-8, should result in no increase in cell death (11), 
and thus no reduction in average lifespan. The motor function of flies overexpressing 
Hip1DANTH was severely diminished (Figure 2.1f). As the ANTH domain is primarily 
involved in endocytosis and can affect cytoskeletal interactions (30, 31), the loss of the 
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ANTH domain likely impairs the proper binding of Hip1 to the cytoskeleton. Cytoskeletal 
movement is in turn responsible for cellular and muscle movements (50), thus the loss of 
the ANTH domain of Hip1 may in fact affect motor ability on the tissue level. This 
suggests a crucial role for the ANTH lipid binding domain in motor function, but not in 
the regulation of lifespan. 
Alternatively, the reduced expression of Hip1 was examined to investigate the effect 
of altered Hip1 levels – which could occur due to a mutation in the Hip1 gene or during 
HD, if the cell recognizes the free Hip1 as non-functional and tags the protein for 
degradation. Flies possessing reduced amounts of normal Hip1 levels display increased 
longevity, but a reduction in motor ability through elav-Gal4 (Figure 2.1c & d). As Hip1 
is involved in initiating caspase-8 mediated apoptotic cell pathways, a reduction in 
protein levels may result in decreased apoptotic cell cycle control (11), thus increasing the 
lifespan of the cell, and therefore the organism. The decline in motor ability can again be 
explained by the loss of the interaction of Hip1 with the cytoskeleton (31), causing 
cytoskeletal dysfunction and affecting locomotor ability of the organism. The effects 
observed suggest a delicate balance of Hip1 protein concentration levels is necessary in 
healthy cells, and altered expression levels affect longevity and motor function. The Hip1 
RNAi lines used in this analysis have also been shown to increase the microchaetae 
density of D. melanogaster, while a loss of function mutation of Hip1 displayed a reduced 
longevity and no change in motor function (51). Still a relatively novel gene in the study 
of Huntington Disease, there is minimal data available on the expression patterns of Hip1. 
As a potential target gene in neurodegenerative disease, an investigation of expression 
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levels in higher organisms with respect to Huntington Disease will aid in the search for 
potential treatment options.  
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Chapter 3 - A Huntington gene in models of Parkinson Disease: Investigating the 
effects of altered Hip1 expression in Drosophila melanogaster 
 
3.1 Introduction 
Neurodegenerative diseases are an increasing problem in today’s ageing society. 
Parkinson Disease (PD) is a progressive neurodegenerative disorder, second in 
prevalence only to Alzheimer Disease (15). The incidence of Parkinson Disease 
increases with age, affecting over 1% of the human population above 65 and 4 to 5% of 
the population over the age of 85 (16). Characterized by loss of cognitive ability and 
motor functions, PD begins with the loss of dopaminergic neurons in the substantia 
nigra of the midbrain, often accompanied by the formation of Lewy bodies (17, 52). PD 
can occur sporadically or through genetic inheritance, in both autosomal-dominant and 
autosomal-recessive patterns (5, 52). A number of genes have been implicated in the 
pathogenesis of Parkinson Disease, including Pink1, Parkin, PGC-1α, PARIS and α-
synuclein just to name a few (5, 20-23), and a number of genes have been associated 
with different patterns of inheritance (5, 53). An investigation of the expression patterns 
of the genes involved in PD and the interactions of their respective proteins can provide 
insights into disease pathogenesis.  
Huntingtin interacting protein 1 Related (Hip1R) was identified as a risk factor for 
PD in a genome wide association study in humans (24, 25). A number of functions have 
been identified for Hip1R, including endocytosis, clathrin assembly, chromosomal 
segregation and apoptosis (29, 54, 55). Low Hip1R expression has been associated with 
decreased survival in cancer patients, and expression of Hip1R in the mouse brain 
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suggests a role for the protein in development (56, 57). Prominent expression of Hip1R 
is present in the midbrain (56), the area in which the dopaminergic neurons are located 
(58), suggesting a potential link to PD development.     
Hip1R is considered an orthologue of Hip1 (Huntingtin interacting protein 1), which 
has been implicated in Huntington Disease (14, 59). Although the Hip1 and Hip1R 
proteins share structural similarity and have some overlapping functions, they play 
somewhat different roles in the cell (26, 27). Hip1 is involved in trafficking, 
endocytosis, neurogenesis, cell survival and apoptotic cell signalling (9, 11-14). 
Bioinformatic analysis of Hip1 and Hip1R revealed that the closest D. melanogaster 
homologue for both genes is Drosophila Hip1 (Figure 1.2). Thus, an investigation of 
altered Hip1 expression on D. melanogaster lifespan and locomotor ability may provide 
insight into both Huntington Disease and Parkinson Disease.  
Implications observed upon overexpression and loss of function of Hip1 in a pan-
neuronal fashion suggested a need to investigate differential expression in more detail. 
To mimic the pathogenesis of Parkinson Disease, in this study the expression of Hip1 in 
the dopaminergic neurons was altered, and the effects on longevity and locomotor 
ability were examined.     
3.2 Materials and Methods 
3.2.1 Drosophila melanogaster stocks and culture 
Drosophila were cultured on a standard media containing 65 g/L cornmeal, 10 g/L 
yeast, 5.5 g/L agar, 50 ml/L fancy grade molasses, 5 ml of 0.1 g/ml methyl 4-
hydroxybenzoate in 95% ethanol and 2.5 ml of propionic acid at 25°C.  
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The UAS-lacZ responder line (42), UAS-GFP responder line (43), ple-Gal4 (60) and 
UAS-Hip1-RNAi32504 (44) lines were obtained from the Bloomington Drosophila Stock 
Centre (University of Indiana, Bloomington, USA). The UAS-Hip1L2, UAS-HipL6 and 
UAS-Hip1S11.2 (ΔANTH) transgenic lines were generated by Justin Moores (14). The 
UAS-Hip1-RNAi106978 (47, 48) was obtained from the Vienna Drosophila Resource Centre 
(Vienna Biocenter, Vienna, USA). Dr. J. Hirsch (University of Virginia) generously 
provided the Ddc-Gal4 HL4.3D and Ddc-Gal4 HL4.36 (61) lines and the combination stock 
Ddc-Gal4 HL4.3D; Ddc-Gal4 HL4.36  was generated by standard genetic means. Stock of 
w1118 was generously provided by Dr. Howard Lipshitz, of the University of Toronto. 
Expression patterns of the fly lines used in this analysis can be found in Table 2. 
On standard media, crosses were set up by placing three to five virgin females of the 
corresponding genotype and two to five Gal4 males together. To increase the number of 
progeny, parental flies were placed on new media at day 2, 4 and 6 post experimental 
initiation. Critical class males were selected. 
3.2.2 Longevity assay 
Male progeny of the critical class genotype were isolated on the day of eclosure and 
maintained on fresh standard media in vials of 25 or less at 25°C. Flies were scored every 
second day for death (N ³ 296). Data was analyzed and survival curves were generated 
using GraphPad Prism 5.0c or 7.0b (GraphPad Software, Inc., San Diego, California, 
USA). A Mantel-Cox test indicated significance (P < 0.05).   
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Table 3.1 – Genotypes, location of transgene insertion and expression patterns used in 
the analysis of Hip1 overexpression and the loss of function of Hip1 expressed in the 
dopaminergic neurons to determine their role in the pathogenesis of Parkinson Disease.  
Genotype 
Insertion 
Chromosome 
Affected 
Chromosome Expression Patterns 
w1118 N/A 1 N/A 
UAS-lacZ 2 1;2 Expresses lacZ under UAS 
control 
UAS-GFP 3 3 Expresses GFP under UAS 
control 
UAS-Hip1-
RNAi106978 
2 1;2 Expresses dsRNAi for Hip1 
under UAS control 
UAS-Hip1-
RNA132504 
3 1;3 Expresses dsRNAi for Hip1 
under UAS control 
UAS-Hip1L2 Unknown Unknown Expresses Hip1 under UAS 
control 
UAS-Hip1L6 Unknown Unknown Expresses Hip1 under UAS 
control 
UAS-Hip1S11.2 Unknown Unknown Expresses Hip1ΔANTH under 
UAS control 
ple-Gal4 3 1;3 Gal4 expressed in dopaminergic 
cells 
Ddc-Gal4HL4.3D 2 1;2 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
Ddc-Gal4HL4.36 3 1;3 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
 Ddc-Gal4HL4.3D; 
Ddc-Gal4HL4.36 
2 & 3 1;2;3 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
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3.2.3 Locomotor assay 
Male progeny of the critical class were isolated on the day of eclosure and maintained 
on fresh standard media in vials of 10 or less at 25°C. Flies were scored for climbing 
ability beginning at day two post eclosion, and at regular seven day intervals afterward. 
To score for climbing ability, flies were placed in glass tubes and given 10 seconds to 
climb. The maximum level that they reached was recorded (20). A climbing index was 
calculated based on these results given the following formula: 
Climbing Index = (nm/N) 
where n=number of flies at level, m=score for the level and N=total number of flies 
climbed (49). 
A total of 50 individuals (N=50) from each genotype were analyzed in groups of 10 
or less. Each group underwent a total of 10 trials, providing a total number of 500 trials 
per genotype per week. This analysis continued until less than 10 flies remained alive or 
flies received a minimum score for two consecutive weeks. Data was analyzed and non-
linear regression curves with a 95% confidence interval were generated using GraphPad 
Prism version 5.0c or 7.0b (GraphPad Software, Inc., San Diego, California, USA). A 
comparison of fits of the non-linear regression curves incorporating the Y-intercept 
(initial climbing ability) and slope (rate of decline in climbing ability) concluded if the 
curves were significantly different (P < 0.05). 
3.3 Results 
3.3.1. Hip1 and Hip1R share similar domains across species 
 Conservation of the ANTH and talin-like structural domains of Hip1 in fruit flies 
and humans suggests similar functions for the protein throughout evolutionary history 
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(14). Considered an orthologue of Hip1, human Hip1R does not have an independent 
Drosophila homologue. However, The ANTH lipid binding domain is highly conserved 
in human Hip1R, while the N-terminus of the protein itself shows a high degree of 
conservation with human and Drosophila Hip1, and they do seem to share similar 
functions, including endocytosis and apoptosis (11, 27, 29, 54). The Hip1R protein is 
shorter and missing the talin-like domain at the C-terminus (Figure 1.2), implicating it in 
cellular functions different than those performed by Hip1 (27, 55). The conservation of 
Hip1 across species provides a model with which to study human disease, and suggests 
that a study of the effects of altered expression of Drosophila Hip1 may apply to both 
human Hip1 and Hip1R.  
3.3.2. Altered Hip1 expression in the dopaminergic neurons affects longevity and 
motor ability 
Directed altered expression of Hip1 in the dopaminergic neurons of D. melanogaster 
can provide insights into the progression of PD. Examination of longevity and locomotor 
ability will reveal the effects of altered gene expression, and can suggest potential 
candidates for disease pathogenesis. The use of ple-Gal4 to drive gene expression in the 
dopaminergic neurons displayed no significant difference in survival between the benign 
UAS-lacZ and UAS-GFP responder lines (Figure 3.1a), both having a median survival of 
70 days. Comparing the UAS-lacZ benign responder with an average lifespan of 70 days 
to the 72 day average lifespan of the responder-less (w1118) displayed a significant 
difference in fly longevity (Figure 3.1a).  An examination of motor ability revealed no 
significant difference in climbing ability between the benign UAS-lacZ and UAS-GFP  
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Figure 3.1 – Altered expression of Hip1 through the ple-Gal4 transgene affects longevity and 
motor function. A, C and E: Longevity assay of Drosophila melanogaster males displaying 
altered Hip1 expression in the dopaminergic neurons. Longevity is shown as percent survival 
(P < 0.05, determined by log rank). The dotted line represents median survival of flies. Error 
bars represent standard error of the mean (N³296). B, D and F: Locomotor assay of D. 
melanogaster males displaying altered Hip1 expression in the dopaminergic neurons. 
Climbing ability was determined via nonlinear curve fit (CI=95%).  Error bars indicate 
standard error of the mean, N = 50. Genotypes are as follows: ple-Gal4; + (w1118), ple-Gal4; 
UAS-lacZ, ple-Gal4; UAS-GFP, ple-Gal4; UAS-Hip1-RNAi106978, ple-Gal4; UAS-Hip1-
RNAi32504, ple-Gal4; UAS-Hip1L2, ple-Gal4; UAS-Hip1L6, ple-Gal4; UAS-Hip1-DANTHS11.2. 
See Appendix D for supplemental data. 
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controls, and a significant decrease in climbing ability of the responder-less w1118 
later in life through ple-Gal4 (Figure 3.1b). As the UAS-lacZ control incorporates the 
activation of the UAS-Gal4 system while expressing a benign responder, it will be used as 
a control for the purpose of this analysis. 
A loss of function analysis of Hip1 through RNAi in ple-Gal4; UAS-Hip1-RNAi106978 
and ple-Gal4; UAS-Hip1-RNAi32504 increased average lifespan to 78 days (Figure 3.1c) 
compared to the 70-day average lifespan of the ple-Gal4; UAS-lacZ control. With ple-
Gal4; UAS-Hip1-RNAi32504, a marked reduction in motor function was observed. This 
significant decrease was not seen in ple-Gal4; UAS-Hip1-RNAi106978 individuals, 
although there did appear to be a slight decline in motor function (Figure 3.1d).  
Analysis of overexpression data of UAS-Hip1L2 and UAS-Hip1L6 in the dopaminergic 
neurons directed by ple-Gal4 displayed a dramatic reduction in average lifespan (56 days 
and 58 days respectively) compared to the UAS-lacZ control (70 days) (Figure 3.1e). 
Overexpression of ple-Gal4; UAS-Hip1DANTH S11.2 in the dopaminergic neurons 
displayed a slight decrease in median lifespan of 68 days (Figure 3.1e). Interestingly, all 
three Hip1 overexpression lines seemed to maintain an increased motor ability until later 
in life, when flies displayed a slight loss of motor function (Figure 3.1f).  
Altered expression of Hip1 in the dopaminergic neurons through Ddc-Gal4HL4.3D 
displayed no significant difference in motor ability between the UAS-lacZ, UAS-GFP and 
“no responder” (w1118) controls (Figure 3.2b). Both Ddc-Gal4HL4.3D; UAS-GFP and Ddc-
Gal4HL4.3D; + displayed an increased median lifespan of 58 and 74 days compared to the 
Ddc-Gal4HL4.3D; UAS-lacZ control (LD50 = 54) (Figure 3.2a). For the purpose of this 
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experiment, the benign UAS-lacZ will be used as the control, as it simulates the use of the 
UAS-Gal4 system, but the responder is benign. Note that extra care must be taken when 
considering a control (62).   
A loss of function of Hip1 analysis through Ddc-Gal4 HL4.3D; UAS-Hip1-RNAi106978 
and Ddc-Gal4 HL4.3D; UAS-Hip1-RNAi32504 displayed an increase in lifespan, having 
median lifespans of 62, and 70 days respectively, compared to the Ddc-Gal4 HL4.3D; UAS-
lacZ control of 54 days (Figure 3.2c). This data trend is similar to the trend observed 
upon expression with ple-Gal4 (Figure 3.1c). The locomotor analysis however did not 
display similar trends, with both Ddc-Gal4 HL4.3D; UAS-Hip1-RNAi106978 and Ddc-Gal4 
HL4.3D; UAS-Hip1-RNAi32504 exhibiting increased climbing ability compared to the Ddc-
Gal4 HL4.3D; UAS-lacZ control (Figure 3.2d). 
Overexpression of Hip1 through Ddc-Gal4HL4.3D displayed a slight increase in 
longevity for Ddc-Gal4HL4.3D; UAS-Hip1L2 (LD50=58) and Ddc-Gal4HL4.3D; UAS-
Hip1S11.2 (LD50=58) compared to the Ddc-Gal4HL4.3D; UAS-lacZ control (LD50=54). 
Ddc-Gal4HL4.3D; UAS-Hip1L6 however, showed a reduction in longevity, with a median 
survival of 44 days (Figure 3.2e). All three critical class male cohorts that directed 
versions of Hip1 overexpression through Ddc-Gal4HL4.3D, Ddc-Gal4 HL4.3D; UAS-Hip1L2, 
Ddc-Gal4 HL4.3D; UAS-Hip1L6, Ddc-Gal4 HL4.3D; UAS-Hip1S11.2 showed an increase in 
locomotor ability compared to the Ddc-Gal4HL4.3D; UAS-lacZ control (Figure 3.2f). 
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Figure 3.2 - Altered expression of Hip1 through the Ddc-Gal4HL4.3D transgene affects 
longevity and motor function. A, C and E: Longevity assay of Drosophila melanogaster 
males displaying altered Hip1 expression in the dopaminergic neurons. Longevity is shown 
as percent survival (P < 0.05, determined by log rank). The dotted line represents median 
survival of flies. Error bars represent standard error of the mean (N³377). B, D and F: 
Locomotor assay of D. melanogaster males displaying altered Hip1 expression in the 
dopaminergic neurons. Climbing ability was determined via nonlinear curve fit (CI=95%).  
Error bars indicate standard error of the mean, N = 50. Genotypes are as follows: Ddc-
Gal4HL4.3D; + (w1118), Ddc-Gal4 HL4.3D; UAS-lacZ, Ddc-Gal4 HL4.3D; UAS-GFP, Ddc-Gal4 
HL4.3D; UAS-Hip1-RNAi106978, Ddc-Gal4 HL4.3D; UAS-Hip1-RNAi32504, Ddc-Gal4 HL4.3D; UAS-
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Hip1L2, Ddc-Gal4 HL4.3D; UAS-Hip1L6, Ddc-Gal4 HL4.3D; UAS-Hip1DANTH S11.2. See 
Appendix E for supplemental data.  
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Expression through Ddc-Gal4HL4.36 revealed no significant difference in lifespan 
between the responder-less, Ddc-Gal4HL4.36; + (LD50 = 58) and those with a benign 
responder Ddc-Gal4HL4.36; UAS-lacZ (LD50 = 64), while the lacZ flies appeared to have 
an increased motor function (Figure 3.3a & b). An increase in median lifespan was 
observed with Ddc-Gal4HL4.36; UAS-GFP (LD50 = 71), while no significant change in 
motor function was observed (Figure 3.3a & b). As Ddc-Gal4HL4.36; UAS-lacZ expresses 
a benign responder, it will serve as a control for the purpose of this analysis. The flies that 
possessed the Ddc-Gal4HL4.36 transgene seemed to have a reduced viability compared to 
the others and a much greater effort to obtain critical class individuals was necessary to 
obtain the required sample size which might influence the results obtained. 
Inhibition of Hip1 expression in the dopaminergic neurons through Ddc-Gal4 HL4.36, 
in Ddc-Gal4 HL4.36; UAS-Hip1-RNAi106978 displays a slight reduction in lifespan (LD50 = 
60) and had no effect on motor ability compared to the Ddc-Gal4 HL4.36; UAS-lacZ control 
(LD50 = 64) (Figure 3.3c & d). However, Ddc-Gal4 HL4.36; UAS-Hip1-RNAi32504 showed 
increased longevity, having a median lifespan of 76 days, and displayed a reduction in 
motor control (Figure 3.3c & d). Overexpression of Hip1L2 in the dopaminergic neurons 
through Ddc-Gal4HL4.36, in Ddc-Gal4 HL4.36; UAS-Hip1L2 males, displayed an increased 
median lifespan of 72 days, and a reduction in motor function compared to the Ddc-
Gal4HL4.36; UAS-lacZ control (Figure 3.3e & f). Ddc-Gal4 HL4.36; UAS-Hip1L6 displayed a 
slight reduction in longevity, having a median lifespan of 60 days, and depreciated 
locomotor function. Ddc-Gal4 HL4.36; UAS-Hip1DANTH S11.2 (LD50 = 62) displayed a 
reduced motor function, but survival was not significantly different when compared to the  
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Figure 3.3 - Altered expression of Hip1 through the Ddc-Gal4HL4.36 transgene affects 
longevity and motor function. A, C and E: Longevity assay of Drosophila melanogaster 
males displaying altered Hip1 expression in the dopaminergic neurons. Longevity is shown 
as percent survival (P < 0.05, determined by log rank). The dotted line represents median 
survival of flies. Error bars represent standard error of the mean (N³324). B, D and F: 
Locomotor assay of D. melanogaster males displaying altered Hip1 expression in the 
dopaminergic neurons. Climbing ability was determined via nonlinear curve fit (CI=95%).  
Error bars indicate standard error of the mean, N = 50. Genotypes are as follows: Ddc-Gal4 
HL4.3D; + (w1118), Ddc-Gal4 HL4.3D; UAS-lacZ, Ddc-Gal4 HL4.3D; UAS-GFP, Ddc-Gal4 HL4.3D; 
UAS-Hip1-RNAi106978, Ddc-Gal4 HL4.3D; UAS-Hip1-RNAi32504, Ddc-Gal4 HL4.3D; UAS-Hip1L2, 
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Ddc-Gal4 HL4.3D; UAS-Hip1L6, Ddc-Gal4 HL4.3D; UAS-Hip1DANTH S11.2. See Appendix F for 
supplemental data.  
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Ddc-Gal4 HL4.36; UAS-lacZ control (Figure 3.3e & f). It is important to note that the 
entire curve, not just the median survival is considered when determining significance. 
A final analysis, this one utilizing a composite line, Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36, 
that was originally constructed to increase the expression of Ddc-Gal4 was completed to 
determine the effects of altered Hip1 expression in the dopaminergic neurons. This 
combined transgenic stock seems to be less active than anticipated based on the results 
observed. No significant difference was observed in a survival analysis comparing Ddc-
Gal4HL4.3D; Ddc-Gal4HL4.36; + (LD50 = 70), Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-lacZ 
(LD50 = 63) and Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-GFP (LD50 = 68) (Figure 3.4a). 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; + flies demonstrated a slight increase in climbing ability 
(Figure 3.4b). For the purpose of this analysis, the flies expressing the benign responder 
(UAS-lacZ), as in Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-lacZ, will function as the control. 
Reduced dopaminergic expression through RNAi in Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1-RNAi32504, males revealed a decrease in motor ability and an increase in  
lifespan (LD50 = 76) compared to Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-lacZ (LD50 = 
63) upon expression through Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36 (Figure 3.4b & c). These  
changes in lifespan and motor ability were not observed upon loss of function of Hip1 in 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-Hip1-RNAi106978 (LD50 = 60) (Figure 3.4b & c).    
Overexpression of full length Hip1 in the dopaminergic neurons through the double 
Ddc-Gal4 transgenes, in Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-Hip1L2 and Ddc-
Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-Hip1L6 flies and of truncated Hip1, in Ddc-Gal4HL4.3D; 
Ddc-Gal4HL4.36; UAS-Hip1DANTHS11.2 flies displayed reduced average lifespans of 52,  
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Figure 3.4 - Altered expression of Hip1 through the combined Ddc-Gal4HL4.3Dand Ddc-
Gal4HL4.36 transgenes affects longevity and motor function. A, C and E: Longevity assay of 
Drosophila melanogaster males displaying altered Hip1 expression in the dopaminergic 
neurons. Longevity is shown as percent survival (P < 0.05, determined by log rank). The 
dotted line represents median survival of flies. Error bars represent standard error of the mean 
(N³322). B, D and F: Locomotor assay of D. melanogaster males displaying altered Hip1 
expression in the dopaminergic neurons. Climbing ability was determined via nonlinear curve 
fit (CI=95%).  Error bars indicate standard error of the mean, N = 50. Genotypes are as 
follows: Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; + (w1118), Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-
lacZ, Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36 ; UAS-GFP, Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36 ; UAS-
Hip1-RNAi106978, Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-Hip1-RNAi32504, Ddc-Gal4HL4.3D; 
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Ddc-Gal4HL4.36; UAS-Hip1L2, Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36 ; UAS-Hip1L6, Ddc-Gal4HL4.3D; 
Ddc-Gal4HL4.36; UAS-Hip1DANTHS11.2. See Appendix G for supplemental data. 
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53 and 60 days respectively, compared to the 63 days displayed by Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-lacZ (Figure 3.4d). Upon examination of locomotor ability, an increase 
in locomotor ability was observed with expression of UAS-Hip1L2, UAS-Hip1L6 and UAS-
Hip1S11.2 via the double Ddc-Gal4 transgenes when compared to the Ddc-Gal4HL4.3D; 
Ddc-Gal4HL4.36; UAS-lacZ control (Figure 3.4e). 
3.4 Discussion 
The progression and pathogenesis of neurodegenerative diseases has long been a 
focus of scientific research. New technology has allowed the discovery of new genes, 
many of which still have unknown functions and implications. Characterized by loss of 
cognitive ability and motor function, the degradation of the dopaminergic neurons and the 
formation of Lewy bodies is the most commonly recognized pathogenic marker of 
Parkinson Disease. Similar symptoms are exhibited by HD patients, although the primary 
cause is suspected to be an expansion of a CAG repeat in the Htt gene, with degeneration 
beginning in the GABAergic neurons (9, 10). While a number of genes have been 
implicated, the molecular mechanisms and cellular pathways behind the progression of 
HD and PD remain largely unknown (7, 8, 15, 17). After being identified as a risk factor 
in a genome wide association study, the precise role of Hip1R in the pathogenesis of 
Parkinson Disease is under investigation (24). Involved in endocytosis, clathrin assembly, 
chromosomal segregation and apoptosis, Hip1R is a great candidate for a role in disease 
progression (29, 54, 55). Hip1R is considered an orthologue of Hip1, which has been 
implicated in the pathogenesis of HD (14, 59). Involved in trafficking, endocytosis, 
neurogenesis and apoptosis, the two proteins share similar but distinctive cellular 
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functions (9, 11-14, 26, 27). An understanding of the functions of Hip1 and Hip1R in the 
pathogenesis of HD and PD will aid in understanding the disease itself.  
D. melanogaster was used as a model to examine the role of Hip1R in PD 
pathogenesis, as the Hip1 protein is conserved across species, sharing domains with 
human Hip1 and Hip1R (Figure 1.2)(14). This protein conservation across species 
suggests a functionally important role, and thus alterations or mutations of this gene may 
have a clinical impact. To investigate the implications of Hip1R in Parkinson disease, 
targeted expression of Hip1 was altered in the dopaminergic neurons of D. melanogaster. 
Loss of function of Hip1 through ple-Gal4 and Ddc-Gal4 generally increased the average 
lifespan of the fly, but depressed locomotor skills (Figure 3.1c, d; 3.2c, d; 3.3c, d & 3.4c, 
d). Cohorts of individuals expressing the inhibitory transgene UAS-Hip1-RNAi32504, 
generally displayed a stronger phenotype than those expressing the RNAi via UAS-Hip1-
RNAi106978 and this may be related to the efficiency of the RNAi transgene or it’s 
inhibitory transcript. In contrast, overexpression of full length Hip1 generally decreased 
the average life span of D. melanogaster, but improved locomotor skills over time 
(Figure 3.1e, f; 3.2e, f; & 3.4e, f). The exception to this was observed with the Ddc-
Gal4HL4.36 (Figure 3.3) that displayed an increased lifespan when directing the expression 
of Hip1L2, and a reduction in motor ability through expression of Hip1L2, Hip1L6 and 
Hip1S11.2.  
In general, groups of males that overexpress the truncated UAS-Hip1DANTH 
displayed results similar to those of overexpression of full length Hip1. This suggests that 
the I/LWEQ domain may be the cause of any changes observed upon expression in the 
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dopaminergic neurons, as loss of the ANTH domain had little effect. As human Hip1R 
lacks the I/LWEQ domain, the role for Hip1R in the pathogenesis of PD should be further 
investigated.  
It should be noted that throughout the experiment Ddc-Gal4HL4.36 flies had a reduced 
viability compared to those bearing other Gal4 transgenes, and multiple crosses and 
repetitions were necessary to obtain the required sample size, possibly affecting the 
lifespan and locomotor ability of the flies, and skewing the results (63). Otherwise, the 
inverse relationship between lifespan and motor ability suggests a delicate balance of 
Hip1 is required, and suggests a role for Hip1 (and potentially Hip1R) in the development 
of the dopaminergic neurons. A change in Hip1 expression during development may 
therefore contribute to the pathogenesis of HD and PD, affecting both length and quality 
of life.  
An investigation of the implications of altered Hip1 and Hip1R expression, and how 
they affect disease progression is needed. Involved in neurogenesis, endocytosis and 
apoptosis, altered expression may produce dramatic changes in cellular function (9, 11, 
13, 14). The investigation of the role of Hip1 in Huntington Disease and Hip1R in 
Parkinson Disease is just beginning, and the impact it may have on the understanding of 
disease pathogenesis and potential treatments is notable. A thorough and precise 
understanding of all genes involved in disease progression, their functions, interactions 
and their implications will greatly advance treatment and potentially provide a cure for 
Parkinson Disease.      
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Chapter 4 – Investigating the role of Huntingtin interacting protein 1 protein 
interactor in Huntington Disease and Parkinson Disease in a Drosophila 
melanogaster model 
 
4.1 Introduction 
Expansion of the polyglutamine tract of Htt in HD patients renders a number of 
the Htt protein’s normal binding partners unable to bind. These binding partners, now 
free in the cell, have the potential to form aggregates and have downstream cellular 
effects (9, 10). One of the normal binding partners of Htt, Huntingtin interacting Protein 
1, is unable to bind to the expanded polyglutamine tract (9). This increases the amount of 
free Hip1 in the cell, which is then able to form aggregates, specifically a complex with 
Huntingtin interacting protein 1 protein interactor (Hippi). Interacting through their 
pDED (coiled coil) domains, this Hip1-Hippi complex activates pro-caspase-8, and has 
the ability to initiate apoptosis (9, 11). Hippi has been implicated in other apoptotic 
pathways, including activation of caspase-1 and caspase-3 (64, 65). On the other hand, 
interaction of Hippi with Apoptin, a chicken anemia virus-encoded protein, seems to 
function in the suppression of apoptosis (66).  The normal function of Hippi has been 
difficult to characterize, but a role has been established for the protein in regulation of 
transcription, Sonic hedgehog signalling, cilia assembly and neuronal development (14, 
67-69). The implication of Hippi in the activation of apoptotic cell pathways and 
potential involvement in neurodegenerative disorders suggests a need to further 
investigate the role of the protein in disease progression, and may provide valuable 
information in the search for treatments and cures.  
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4.2 Materials and Methods 
4.2.1 Drosophila melanogaster stocks and culture 
The UAS-lacZ responder line (42), elav-Gal4 (45), GawBl(3)31-1 (46) and ple-Gal4 
(60) transgenic lines were obtained from the Bloomington Drosophila Stock Centre 
(University of Indiana, Bloomington, USA). The UAS-Hippi-RNAi (Che-13) line (47) 
was obtained from the Vienna Drosophila Resource Centre (Vienna Biocenter, Vienna, 
USA). The Ddc-Gal4 HL4.3D and Ddc-Gal4 HL4.36  lines (61) were provided by Dr. J. 
Hirsch at the University of Virginia, and the Ddc-Gal4 HL4.3D; Ddc-Gal4 HL4.36 
combination line was generated by standard genetic means. The expression patterns of fly 
lines used in this analysis and the place of insertion can be found in Table 3. 
D. melanogaster stocks were cultured and maintained on media consisting of 65 g/L 
cornmeal, 10 g/L yeast, 5.5 g/L agar and 50 ml/L fancy grade molasses, 5 ml of 0.1 g/ml 
methyl 4-hydroxybenzoate in 95% ethanol and 2.5 ml of propionic acid at 25°C. All 
experiments were at 25° C. 
Crosses were set up by placing three to five UAS virgin females of the corresponding 
genotype and two to five Gal4 males together on standard media. Parental flies were 
placed on new media at day 2, 4 and 6 after experimental set up, to increase the number 
of progeny. Critical class males were selected. 
4.2.2 Longevity assay 
Critical class male progeny were separated on the day of eclosure and maintained at 
25°C on standard media in vials of 25 or less. Flies were scored every second day for the 
presence of deceased individuals, and media was regularly changed to ensure ideal 
conditions (N ³ 208). Data was analyzed using GraphPad Prism 5.0c or 7.0b (GraphPad 
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Software, Inc., San Diego, California, USA), survival curves were generated and a 
Mantel-Cox test was performed to determine significance (P < 0.05).   
Table 4.1 - Genotypes, location of transgene insertion and expression patterns used in the 
analysis of the loss of function of Hippi expressed in a pan-neuronal fashion and in the 
dopaminergic neurons to determine their role in the pathogenesis of neurodegenerative 
disease. 
Genotype Insertion 
Chromosome 
Affected 
Chromosome 
Expression Patterns 
UAS-lacZ 2 1;2 Expresses lacZ under UAS control 
UAS-Hippi-
RNAi 
2 1;2 Expressed dsRNAi for Hippi 
under UAS control 
elav-Gal4 1 1 Gal4 expressed in all tissues of 
the embryonic nervous system 
beginning at stage 12 
GawBl(3)31-1 3 1;3 Gal4 expressed in neuroblasts and 
neurons 
ple-Gal4 3 1;3 Gal4 expressed in dopaminergic 
cells 
Ddc-Gal4HL4.3D 2 1;2 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
Ddc-Gal4HL4.36 3 1;3 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
 Ddc-
Gal4HL4.3D; 
Ddc-Gal4HL4.36 
2 & 3 1;2;3 Gal4 expressed in the 
dopaminergic and serotonergic 
neurons 
 
4.2.3 Locomotor assay 
Critical class male progeny were separated on the day of eclosure and maintained at 
25°C on fresh standard media in vials of 10 or less. Starting at day 2 post eclosion, and at 
regular seven day intervals afterward, flies were scored for climbing ability by placing 
them in glass tubes, and recording the maximum level reached within 10 seconds (20). A 
climbing index was calculated using the formula described below:  
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Climbing Index = (nm/N) 
where n=number of flies at level, m=score for the level and N=total number of flies 
climbed (49). 
50 individuals from each genotype were analyzed in groups of 10 or less (N = 50). 
Each group underwent a total of 10 trials, providing a total trial number of 500 flies per 
genotype per week. This analysis was continued until less than 10 flies remained alive or 
flies received a minimum score for two consecutive sessions. A climbing curve (non-
linear regression curve) was generated using GraphPad Prism 5.0c or 7.0b software 
(GraphPad Software, Inc., San Diego, California, USA). A comparison of fits of the non-
linear regression curves taking the Y-intercept (initial climbing ability) and slope (rate of 
decline in climbing ability) into consideration concluded if the curves were significantly 
different (P < 0.05). 
4.3 Results 
 
Loss of function of Hippi (Che-13), in elav-Gal4; UAS-Hippi-RNAi revealed a 
reduction in both lifespan (median lifespan = 64 days) and locomotor function compared 
to the elav-Gal4; UAS-lacZ control (median lifespan = 70 days) (Figure 4.1a & b), 
establishing a role for Hippi in HD pathogenesis.  Loss of function of Hippi (Che-13), in 
GawBl(3)31-1; UAS-Hippi-RNAi revealed an increase in average lifespan (LD50 = 64) and 
an increase in motor function compared to the UAS-lacZ control, providing further 
evidence that Hippi may play a role in neurogenesis and disease pathogenesis, but its 
expression patterns may affect the outcome. A loss of function analysis of Hippi (Che-
13), in ple-Gal4; UAS-Hippi-RNAi males resulted in a lifespan of 70 days, identical to the  
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Figure 4.1 – Altered expression of Hippi through the elav-Gal4 and the GawBl(3)3-1 -Gal4  
transgene affects longevity and motor function. A and C: Longevity assay of Drosophila 
melanogaster males displaying reduced Hippi expression in a pan-neuronal fashion. 
Longevity is shown as percent survival (P < 0.05, determined by log rank). The dotted line 
represents median survival of flies. Error bars represent standard error of the mean (N³311). 
B and D: Locomotor assay of D. melanogaster males displaying reduced Hippi expression in 
a pan-neuronal fashion. Climbing ability was determined via nonlinear curve fit (CI=95%).  
Error bars indicate standard error of the mean, N = 50. Genotypes are as follows: elav-Gal4; 
UAS-lacZ, elav-Gal4; UAS-Hippi-RNAi, GawBl(3)3-1; UAS-lacZ and GawBl(3)31-1; UAS-Hippi-
RNAi. See Appendix H for supplemental data. 
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Figure 4.2 – Altered expression of Hippi in the dopaminergic neurons affects longevity and 
motor function. A, C, E and G: Longevity assay of D. melanogaster males displaying 
reduced Hippi expression in the dopaminergic neurons. Longevity is shown as percent 
survival (P < 0.05, determined by log rank). The dotted line represents median survival of 
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flies. Error bars represent standard error of the mean (N³208). B, D, F and G: Locomotor 
assay of D. melanogaster males displaying reduced Hippi expression in the dopaminergic 
neurons. Climbing ability was determined via nonlinear curve fit (CI=95%).  Error bars 
indicate standard error of the mean, N = 50. Genotypes are as follows: ple-Gal4; UAS-lacZ, 
ple-Gal4; UAS-Hippi-RNAi, Ddc-Gal4 HL4.3D; UAS-lacZ, Ddc-Gal4 HL4.3D; UAS-Hippi-RNAi, 
Ddc-Gal4 HL4.3D; UAS-lacZ, Ddc-Gal4 HL4.3D; UAS-Hippi-RNAi, Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-lacZ and Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-Hippi-RNAi. See Appendix I 
for supplemental data.  
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UAS-lacZ control (Figure 4.2a). Locomotor ability of UAS-Hippi-RNAi flies remained 
relatively steady until death, displaying an increase in motor function compared to UAS-
lacZ (Figure 4.2b). Loss of function of Hippi (Che-13) directed to dopaminergic (and 
serotonergic) neurons in Ddc-Gal4 HL4.3D; UAS-Hippi-RNAi critical class cohorts 
displayed a reduction in median lifespan (LD50 = 50) and an increase in locomotor 
ability (Figure 4.2c & d). A comparison of the inhibition of Hippi in Ddc-Gal4 HL4.36; 
UAS-Hippi-RNAi flies revealed an increased survival with a median lifespan of 68 days 
and a decline in motor function compared to UAS-lacZ (LD50 = 64) (Figure 4.2e & f).  
Finally, a reduction in Hippi expression in Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-
Hippi-RNAi displayed a reduction in lifespan (LD50 = 58) and motor ability compared to 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; UAS-lacZ (LD50 = 63) (Figure 4.2g & h). 
4.4 Discussion 
 
The loss of function of Hippi expressed in a pan-neuronal fashion and in the 
dopaminergic neurons displayed effects on longevity and motor control, but the results 
are inconclusive, varying based on the transgene used to drive expression. This suggests 
that Hippi may play a role in neurodegenerative disease, but further investigation into the 
role of Hippi in HD pathogenesis is needed. Investigations into the effects of Hip1 and 
Hippi expression levels in higher organisms may be beneficial in the search for a cure and 
treatments for HD. The loss of function of Hippi through the pan-neuronal elav-Gal4 
transgene displayed a reduction in longevity and motor ability (Figure 4.1a, b), while loss 
of function with the GawBl(3)31-1 transgene displayed an increase in longevity and motor 
ability (Figure 4.1c & d). Loss of function in the dopaminergic neurons displayed 
inconclusive results, with increases and decreases in lifespan and motor ability varying 
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based on the transgene (Figure 4.2). Although no conclusive results can be drawn from 
this data, it is plausible that the regulatory role of Hippi and its implication in the 
activation of apoptosis may contribute to the results observed (11, 14, 68). More data is 
needed to determine the role of Hippi in the pathogenesis of neurodegenerative disease. It 
would be beneficial to investigate the combined effects of altered Hip1 and Hippi 
expression, to determine the effects on a cellular and tissue level.  
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Chapter 5 - Summary 
 
The search for treatments and cures for neurodegenerative diseases is ongoing, and 
the use of model organisms provides a simple way to investigate the consequences of the 
disease pathways. The reduction in D. melanogaster lifespan and motor ability observed 
upon pan-neuronal overexpression of Hip1 levels is an attempt to mimic the effects seen 
in HD patients, as the expansion of the polyglutamine tract results in increased 
cytoplasmic Hip1 (9).  Flies subjected to loss of function of Hip1 displayed an increased 
average lifespan and reduced motor ability, providing a model of neurodegenerative 
disease.  This provides a clue into the role that Hip1 plays in the cell and how it may 
contribute to a number of symptoms associated with HD and neurodegenerative disease. 
Further investigation into the role of Hip1 in healthy individuals and the mechanism by 
which its expression is altered in diseased individuals may lead to novel treatment options 
for HD patients. 
The conservation of Hip1 and Hip1R across species makes investigating the effects 
of altered Hip1 expression specifically in the dopaminergic neurons possible (14). This 
can provide a model of Parkinson Disease, and the results observed are similar to those 
seen in pan-neuronal expression; an increase in lifespan and reduction in motor ability 
upon loss of function of Hip1, and a reduction in lifespan upon overexpression. 
Interestingly, overexpression of Hip1 in the dopaminergic neurons increases average 
motor ability, suggesting that an increased level of Hip1 in the dopaminergic neurons 
may actually be beneficial in terms of motor skills, but still reduces average lifespan. The 
current understanding of the role of Hip1R in Parkinson Disease is limited, and 
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expanding on this knowledge may prove beneficial in the search for novel treatments and 
cures for PD.  
Investigating the loss of Hippi expression was inconclusive, providing inconsistent 
results dependent upon the Gal4 transgene utilized. As the Gal4 transgenes possess 
different expression patterns, the possibility remains that loss of function of Hippi in 
other neuronal patterns, such as through arm-Gal4 or Ple-Gal4 affects longevity and 
motor ability, and that interactions of Hippi with other proteins is vital for neuronal 
development (51, 62).  The observation that reduced Hippi expression altered the lifespan 
and motor ability of flies suggests a need for further investigation into its effects on 
neurodegenerative disease. As a binding partner of Hip1, and with the Hip1-Hippi 
complex potentially involved in the initiation of apoptosis, the altered effects of Hippi 
expression could contribute to disease phenotypes (11). A more in depth understanding of 
the role of Hippi and the effects of its altered expression on the cell is needed to broaden 
our knowledge of HD pathogenesis.   
Neurodegenerative diseases are an increasing problem in today’s ageing population, 
and the molecular mechanisms and cellular pathways of many are still under 
investigation.  The implication of Hip1 in Huntington Disease and Hip1R in Parkinson 
Disease may be of clinical significance, as its expression affects the lifespan and motor 
ability of Drosophila melanogaster. Investigation into the role of Hip1 and Hip1R in the 
pathogenesis of neurodegenerative disease may provide novel treatment targets and 
therapeutic options. 
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Appendix A- Supplemental Data for Figure 1.2 
 
A1. Protein sequence alignment of Drosophila melanogaster Hip1 and Homo sapiens 
Hip1 and Hip1R. Alignment performed in ClustalW2. 
% Similarity Drosophila Hip1 and Human Hip1: 96% 
% Similarity Drosophila Hip1 and Human Hip1R: 31% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Drosophila      MATHAEKEFYHLN---------------------VSVSKALNGLEAPLKTKHARSIIIMI 39 
Homo            MKQVPNPLPKVLSRRGVGAGLEAAERESFERTQTVSINKAINTQEVAVKEKHARTCILGT 60 
Hip1R           MEARFSPINQILP--------------WCRQDLAISISKAINTQEAPVKEKHARRIILGT 46 
                *    .     *                      :*:.**:*  *..:* ****  *:   
 
Drosophila      HKAKEAKTFWMIISRQPLMQSRFTAWKFSHLLHKVLREGHESAIRHSQSHKKMILEVGKM 99 
Homo            HHEKGAQTFWSVVNRLPLSSNAVLCWKFCHVFHKLLRDGHPNVLKDSLRYRNELSDMSRM 120 
Hip1R           HHEKGAFTFWSYAIGLPLPSSSILSWKFCHVLHKVLRDGHPNVLHDCQRYRSNIREIGDL 106 
                *: * * ***      ** .. . .***.*::**:**:** ..::..  ::. : ::. : 
 
Drosophila      WGLLQDDIGCCIQAYSKLLATKLNFHDKNRMFPGTLNISFTELFIAVDRDLNYCFQLCVE 159 
Homo            WGHLSEGYGQLCSIYLKLLRTKMEYHTKNPRFPGNLQMSDRQLDEAGESDVNNFFQLTVE 180 
Hip1R           WGHLHDRYGQLVNVYTKLLLTKISFHLKHPQFPAGLEVTDEVLEKAAGTDVNNIFQLTVE 166 
                ** * :  *   . * *** **:.:* *:  **. *:::   *  *   *:*  *** ** 
 
Drosophila      IFDYLEDIIALQLTIFSSMEKYRMSSMTPQGQCRLAPIVCLIQDSNALYDLSVRLMFKLH 219 
Homo            MFDYLECELNLFQTVFNSLDMSRSVSVTAAGQCRLAPLIQVILDCSHLYDYTVKLLFKLH 240 
Hip1R           MFDYMDCELKLSESVFRQLNTAIAVSQMSSGQCRLAPLIQVIQDCSHLYHYTVKLLFKLH 226 
                :***::  : *  ::* .::     *  . *******:: :* *.. **. :*:*:**** 
 
Drosophila      DGVPYDVVSGHRDRFHGLFLKLKSFYNNVRPLQYFKDLITIPELPDSSPNFKSQNDFTSY 279 
Homo            SCLPADTLQGHRDRFMEQFTKLKDLFYRSSNLQYFKRLIQIPQLPENPPNFLRASALSEH 300 
Hip1R           SCLPADTLQGHRDRFHEQFHSLRNFFRRASDMLYFKRLIQIPRLPEGPPNFLRASALAEH 286 
                . :* *.:.******   * .*:.:: .   : *** ** **.**:..***   . ::.: 
 
Drosophila      VPPVVHVPQEPDPVVEDLVDTNNHELEAFSQAQQQLSMLEGIISEKEASIEELSFKLDAM 339 
Homo            ISPVVVIPAEASSPDSEPVLEKDDLMDMDASQQNLFDNKFDDIFG--------------- 345 
Hip1R           IKPVVVIPEEAPEDE-----EPENLIEISTGPPAGEPVVVADLFD--------------- 326 
                : *** :* *.           :. ::  :            :                  
 
Drosophila      QKNFDALQQSYRHDVQELQQNNTVLSNDLVLAREMCATFRMQNDDLEMQLNQNPILLQKA 399 
Homo            --------SSFSSDPFNFNSQNGVNK-----------------DEKDHLIERLYREISGL 380 
Hip1R           --------QTFGP-------PNGSVK-----------------DDRDLQIESLKREVEML 354 
                        .::          *   .                 *: :  ::     :.   
 
Drosophila      MEEEEKHKLSSEKFNKLKTLYTKIRDEHIQLLREQSDCNKSLNKEKQVNSQLLLETKELT 459 
Homo            KAQLENMKTESQRV-------------VLQLKGHVSELEADLAEQQHLRQQAADDCEFLR 427 
Hip1R           RSELEKIKLEAQRY-------------IAQLKSQVNALEGELEEQRKQKQKALVDNEQLR 401 
                  : *: * .:::                **  . .  : .* :::: ..:   : : *  
 
Drosophila      NEISKIKVNVEEKEKTNLILQKQIEEHKEKIAHLEAVKNEMKEKFDDVVKQKEIQELDII 519 
Homo            AELDELRRQREDTEKA----QRSLSEIERKAQANEQRYSKLKEKYSELVQNH-------- 475 
Hip1R           HELAQLRAAQLEGERS----QGLREEAERKASATEARYNKLKEKHSELVHVH-------- 449 
                 *: :::    : *::    *   .* :.*    *   .::***..::*: :         
 
Drosophila      STSENLRLNCLKVEELNGNLNDTLEKLSNAESQINAKTEDIEKMLKAFEAEKALLLTQIE 579 
Homo            ------------------------ADLLRKNAEVTKQVSMARQAQVDLEREKKELEDSLE 511 
Hip1R           ------------------------AELLRKNADTAKQLTVTQQSQEEVARVKEQLAFQVE 485 
                                         .* . :::   :    .:    .   *  *  .:* 
 
Drosophila      QQSVESKSHSEAQNAQLQEIMDNLEQKDKEFNEVKLQLSSAESQISLKALEIQNNLKAFE 639 
Homo            RISDQGQRKTQEQLEVLESLKQELATSQRELQVLQGSLETSA----QSEANWAAEFAELE 567 
Hip1R           QVKRESELKLEEKSDQLEKLKRELEAKAGELARAQEALSHTE----QSKSELSSRLDTLS 541 
                : . :.: : : :   *:.:  :*  .  *:   :  *. :      .  :   .:  :. 
 
Drosophila      AEKSVLLTKIEQLGIEHKNNSEAQNAQLQLTLNNLEQNESALQQTQEIVNQLRQENASAG 699 
Homo            KERDSLVSGAAHR-----------EEELSALRKELQDTQLKLASTEESMCQLAKDQRKML 616 
Hip1R           AEKDALSGAVRQR-----------EADLLAAQSLVRETEAALSREQQRSSQEQGE----- 585 
                 *:. *     :            : :*    . :.:.:  *   ::   *   :      
 
Drosophila      QRNEDLQSKLSLTEVKLTQATQQIDAVTSSYQICSTDLSELRKLVIKTVKEICNSKLSGS 759 
Homo            -----LVGSRKAAEQVIQDALNQLEEPPL-------------------------ISCAGS 646 
Hip1R           -----LQG--RLAERVWPPQMQQHH----------------------------------- 603 
                     * .    :*       :* .                                    
 
Drosophila      EQQPLDAVPNIIREMETILNKFNNASAINYVASTEGLQNVMYLGYVFIKLYDQCDVIYKT 819 
Homo            ADHLLSTVTSISSCIEQLEKSWS-----QYLACPEDISGFLHSITLLAHLTSDAIAHGAT 701 
Hip1R           ------------------------------------------------------------ 
                                                                             
 
Drosophila      TTAIETGQEIFSKTNLLCTDICQLFQYLLNNETKEPERQKTITDIQTKLRDIEKLIEKIK 879 
Homo            TCLRAPPEPADSLTEACKQYGRETLAYLASLEEEGSLENADSTAMRNCLSKIKAIGEELL 761 
Hip1R           ------------------------------------------------------------ 
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Appendix B - Supplemental data for Figure 2.1 
 
Table B1. Statistical analysis and comparison of longevity between the UAS-lacZ control 
and altered Hip1 expression in D. melanogaster expressed through elav-Gal4. 
 
B1.1. Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
elav-Gal4; + 366 70 0.0368 Yes 
elav-Gal4; UAS-lacZ 315 70 N/A N/A 
elav-Gal4; UAS-GFP 401 52 <0.0001 Yes 
elav -Gal4; UAS-Hip1-
RNAi106978 
295 78 <0.0001 Yes 
elav-Gal4; UAS-Hip1-
RNAi32504 
371 70 0.1199 No 
elav-Gal4; UAS-Hip1L2 326 60 <0.0001 Yes 
elav-Gal4; UAS-Hip1L6 333 54 <0.0001 Yes 
elav-Gal4; UAS-Hip1S11.2 301 70 0.1383 No 
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Table B2. Statistical analysis and comparison of locomotor ability between the UAS-lacZ 
control and altered Hip1 expression in D. melanogaster expressed through elav-Gal4. 
 
B2.1 Climbing ability at 25°C 
 
Genotype Slope (k) Standard 
error 
95% Confidence 
interval 
R2 p-value Significant 
elav-Gal4; + 0.02975 0.002844 0.02466 to 
0.03509 
0.7539 <0.0001 Yes 
elav-Gal4; UAS-lacZ 0.06359 0.008349 0.04609 to 
0.08364 
0.6669 N/A N/A 
elav-Gal4; UAS-GFP 0.01946 0.00275 0.01429 to 
0.02462 
0.574 <0.0001 Yes 
elav-Gal4; UAS-Hip1-
RNAi106978 
0.01256 0.001983 0.00897 to 
0.01626 
0.4912 <0.0001 Yes 
elav-Gal4; UAS-Hip1-
RNAi32504 
0.01793 0.0018 0.01478 to 
0.02124 
0.6814 <0.0001 Yes 
elav-Gal4; UAS-Hip1L2 0.01975 0.004955 0.008783 to 
0.03136 
0.2736 0.0004 Yes 
elav-Gal4; UAS-Hip1L6 0.02831 0.002668 0.02356 to 
0.03338 
0.7721 <0.0001 Yes 
elav-Gal4; UAS-
Hip1S11.2 
0.02117 0.003288 0.01509 to 
0.02757 
0.6051 <0.0001 Yes 
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Appendix C – Supplemental data for Figure 2.2 
 
Table C1. Statistical analysis and comparison of longevity between the UAS-lacZ control 
and altered Hip1 expression in D. melanogaster expressed through GawBl(3)31-1. 
 
C1.1. Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
GawBl(3)31-1; + 322 52 0.7466 No 
GawBl(3)31-1; UAS-lacZ 383 48 N/A N/A 
GawBl(3)31-1; UAS-GFP 313 52 0.4768 No 
GawBl(3)31-1; UAS-Hip1-
RNAi106978 
269 46 0.4018 No 
GawBl(3)31-1; UAS-Hip1-
RNAi32504 
326 55 0.5759 No 
GawBl(3)31-1; UAS-Hip1L2 385 56 0.1423 No 
GawBl(3)31-1; UAS-Hip1L6 270 52 0.2574 No 
GawBl(3)31-1; UAS-Hip1S11.2 336 58 0.0061 Yes 
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Table C2. Statistical analysis and comparison of locomotor ability between the UAS-lacZ 
control and altered Hip1 expression in D. melanogaster expressed through GawBl(3)31-1. 
 
C2.1. Longevity at 25°C 
 
Genotype Slope 
(k) 
Standard 
error 
95% Confidence 
interval 
R2 p-value Significant 
GawBl(3)31-1; + 0.02299 0.00258 0.01780 to 
0.02817 
0.6277 0.0024 Yes 
GawBl(3)31-1; UAS-lacZ 0.02342 0.002958 0.01751 to 
0.02934 
0.5906 N/A N/A 
GawBl(3)31-1; UAS-GFP 0.01929 0.003806 0.01161 to 
0.02698 
0.3826 0.089 No 
GawBl(3)31-1; UAS-
Hip1-RNAi106978 
0.03422 0.005982 0.02206 to 
0.04638 
0.4458 0.2025 No 
GawBl(3)31-1; UAS-
Hip1-RNAi32504 
0.0214 0.001862 0.01767 to 
0.02513 
0.7536 0.0008 Yes 
GawBl(3)31-1; UAS-
Hip1L2 
0.02681 0.003852 0.01904 to 
0.03458 
0.5407 0.4355 No 
GawBl(3)31-1; UAS-
Hip1L6 
0.0372 0.005401 0.02625 to 
0.04815 
0.5525 0.0987 No 
GawBl(3)31-1; UAS-
Hip1S11.2 
0.02916 0.00463 0.01978 to 
0.03854 
0.5203 0.0089 Yes 
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Appendix D – Supplemental data for Figure 3.1 
 
Table D1. Statistical analysis and comparison of longevity between the UAS-lacZ control 
and altered Hip1 expression in D. melanogaster expressed through ple-Gal4. 
 
D1.1. Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
ple-Gal4; + 371 72 0.0001 Yes 
ple-Gal4; UAS-lacZ    362 70 N/A N/A 
ple-Gal4; UAS-GFP 305 70 0.3774 No 
ple-Gal4; UAS-Hip1-
RNAi106978     
296 78 <0.0001 Yes 
ple-Gal4; UAS-Hip1-
RNAi32504     
351 78 <0.0001 Yes 
ple-Gal4; UAS-Hip1L2    493 56 <0.0001 Yes 
ple-Gal4; UAS-Hip1L6  342 58 <0.0001 Yes 
ple-Gal4; UAS-Hip1S11.2 324 68 0.0003 Yes 
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Table D2. Statistical analysis and comparison of locomotor ability between the UAS-lacZ 
control and altered Hip1 expression in D. melanogaster expressed through ple-Gal4. 
 
D2.1 Climbing ability at 25°C 
 
Genotype Slope (k) Standard 
error 
95% 
Confidence 
interval 
R2 p-value Significant 
ple-Gal4; + 0.07465 0.008107 0.06013 to 
0.09088 
0.6987 0.0021 Yes 
ple-Gal4; UAS-lacZ    0.07167 0.01303 0.0415 to 
0.1143 
0.4255 N/A N/A 
ple-Gal4; UAS-GFP 0.04549 0.005235 0.03502 to 
0.05596 
0.6057 0.2612 No 
ple-Gal4; UAS-Hip1-
RNAi106978     
0.05054 0.007991 0.03434 to 
0.06673 
0.5142 0.1441 No 
ple-Gal4; UAS-Hip1-
RNAi32504     
0.04469 0.004311 0.03606 to 
0.05332 
0.7715 <0.0001 Yes 
ple-Gal4; UAS-Hip1L2    0.03066 0.004132 0.02238 to 
0.03894 
0.516 0.0002 Yes 
ple-Gal4; UAS-Hip1L6  0.05639 0.00587 0.04462 to 
0.06817 
0.7123 0.0001 Yes 
ple-Gal4; UAS-Hip1S11.2 0.03877 0.005484 0.02777 to 
0.04976 
0.521 <0.0001 Yes 
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Appendix E – Supplemental data for Figure 3.2 
 
Table E1. Statistical analysis of longevity between the UAS-lacZ control and altered Hip1 
expression in D. melanogaster expressed through Ddc-Gal4HL4.3D. 
 
E1.1 Longevity at 25°C 
 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
Ddc-Gal4 HL4.3D; + 394 74 <0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-lacZ 692 54 N/A N/A 
Ddc-Gal4 HL4.3D; UAS-GFP 416 58 <0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1-
RNAi106978 
504 62 <0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1-
RNAi32504 
453 70 <0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1L2 862 58 0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1L6 377 44 <0.0001 Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1S11.2 612 
 
58 <0.0001 Yes 
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Table E2. Statistical analysis of locomotor ability between the UAS-lacZ control and 
altered Hip1 expression in D. melanogaster expressed through Ddc-Gal4 HL4.3D. 
 
E2.1 Climbing ability at 25°C 
 
 
  
Genotype Slope 
(k) 
Standard 
error 
95% 
Confidence 
interval 
R2 p-
value 
Significant 
Ddc-Gal4HL4.3D; + 0.04345 0.00719 0.02889 to 
0.05801 
0.5692 0.229 No 
Ddc-Gal4 HL4.3D; UAS-lacZ 0.05996 0.01053 0.03851 to 
0.08142 
0.585 N/A N/A 
Ddc-Gal4 HL4.3D; UAS-GFP 0.0374 0.01345 0.007436 to 
0.06736 
0.4777 0.096
5 
No 
Ddc-Gal4 HL4.3D; UAS-Hip1-
RNAi106978 
0.03083 0.0069 0.01672 to 
0.04494 
0.3903 0.046
6 
Yes 
Ddc-Gal4 HL4.3D; UAS-Hip1-
RNAi32504 
0.03821 0.00492 0.02822 to 
0.04821 
0.639 0.004
7 
Yes 
Ddc-Gal4 HL4.3D; UAS-
Hip1L2 
0.03338 0.007502 0.01804 to 
0.04872 
0.3467 0.016
7 
Yes 
Ddc-Gal4 HL4.3D; UAS-
Hip1L6 
0.04813 0.009068 0.02959 to 
0.06668 
0.4892 0.000
2 
Yes 
Ddc-Gal4 HL4.3D; UAS-
Hip1S11.2 
0.02529 0.003785 0.01762 to 
0.03295 
0.5246 <0.00
01 
Yes 
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Appendix F – Supplemental data for Figure 3.3 
 
Table F1. Statistical analysis of longevity between the UAS-lacZ control and altered Hip1 
expression in D. melanogaster expressed through Ddc-Gal4 HL4.36. 
 
F1.1 Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
Ddc-Gal4HL4.36; + 404 58 0.165 No 
Ddc-Gal4HL4.36; UAS-lacZ 366 64 N/A N/A 
Ddc-Gal4HL4.36; UAS-GFP 328 71 0.0036 Yes 
Ddc-Gal4HL4.36; UAS-Hip1-
RNAi106978 
399 60 0.0038 Yes 
Ddc-Gal4HL4.36; UAS-Hip1-
RNAi32504 
324 76 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-Hip1L2 333 72 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-Hip1L6 324 60 0.0175 Yes 
Ddc-Gal4HL4.36; UAS-Hip1S11.2 388 62 0.918 No 
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Table F2. Statistical analysis of locomotor ability between the UAS-lacZ control and 
altered Hip1 expression in D. melanogaster expressed through Ddc-Gal4HL4.36. 
 
F2.1 Climbing ability at 25°C 
 
Genotype Slope (k) Standard 
error 
95% 
Confidence 
interval 
R2 p-value Significant 
Ddc-Gal4HL4.36; + 0.04906 0.004264 0.04053 to 
0.05759 
0.8096 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-lacZ 0.03101 0.005868 0.01921 to 
0.04280 
0.3459 N/A N/A 
Ddc-Gal4HL4.36; UAS-GFP 0.03623 0.007135 0.02194 to 
0.05051 
0.3295 0.0503 No 
Ddc-Gal4HL4.36; UAS-
Hip1-RNAi106978 
0.02434 0.004102 0.01603 to 
0.03266 
0.3697 0.2717 No 
Ddc-Gal4HL4.36; UAS-
Hip1-RNAi32504 
0.04579 0.005176 0.03544 to 
0.05613 
0.6938 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-
Hip1L2 
0.02945 0.00345 0.02253 to 
0.03637 
0.5891 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-
Hip1L6 
0.0624 0.00849 0.04535 to 
0.07945 
0.6841 <0.0001 Yes 
Ddc-Gal4HL4.36; UAS-
Hip1S11.2 
0.03695 0.004766 0.02739 to 
0.04651 
0.5984 <0.0001 Yes 
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Appendix G – Supplemental data for Figure 3.4 
 
 
Table G1. Statistical analysis of longevity between the UAS-lacZ control and altered Hip1 
expression in D. melanogaster expressed through Ddc-Gal4HL4.3D plus Ddc-Gal4HL4.36. 
 
G1.1 Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; + 354 70 0.1223 No 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-lacZ 
408 63 N/A N/A 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-GFP 
371 68 0.5221 No 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1-RNAi106978 
359 60 0.0051 Yes 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1-RNAi32504 
345 76 <0.0001 Yes 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1L2 
363 52 <0.0001 Yes 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1L6 
322 53 <0.0001 Yes 
Ddc-Gal4HL4.3D; Ddc-Gal4HL4.36; 
UAS-Hip1S11.2 
326 60 0.0083 Yes 
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Table G2. Statistical analysis of locomotor ability between the UAS-lacZ control and 
altered Hip1 expression in D. melanogaster expressed through Ddc-Gal4HL4.3D plus Ddc-
Gal4HL4.36. 
 
G2.1 Climbing ability at 25°C 
 
Genotype Slope (k) Standard 
error 
95% 
Confidence 
interval 
R2 p-value Significant 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; + 
0.0379 0.003417 0.03105 to 
0.04474 
0.7887 0.0002 Yes 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-lacZ 
0.05062 0.005911 0.03876 to 
0.06248 
0.7196 N/A N/A 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-GFP 
0.05519 0.006878 0.04137 to 
0.069 
0.6203 0.2844 No 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hip1-
RNAi106978 
0.04804 0.004997 0.03801 to 
0.05806 
0.6913 0.5548 No 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hip1-
RNAi32504 
0.01956 0.002482 0.01459 to 
0.02453 
0.5752 <0.0001 Yes 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hip1L2 
0.02547 0.004542 0.01628 to 
0.03466 
0.4673 0.0002 Yes 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hip1L6 
0.0438 0.01304 0.01723 to 
0.07037 
0.2855 0.3946 No 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hip1S11.2 
0.02968 0.004912 0.01974 to 
0.03961 
0.4981 0.0527 Yes 
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Appendix H – Supplemental data for Figure 4.1  
 
 
Table H1. Statistical analysis of longevity between the UAS-lacZ control and reduced 
Hippi expression in D. melanogaster expressed through elav-Gal4 and GawBl(3)31-1. 
 
H1.1 Longevity at 25°C 
 
Genotype Number 
of Flies 
(N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
elav-Gal4; UAS-lacZ 315 70 N/A N/A 
elav -Gal4; UAS-Hippi-RNAi 332 64 <0.0001 Yes 
GawBl(3)31-1; UAS-lacZ 383 48 N/A N/A 
GawBl(3)31-1; UAS-Hippi-
RNAi 
311 64 <0.0001 Yes 
 
 
 
 
Table H2. Statistical analysis of locomotor ability between the UAS-lacZ control and 
reduced Hippi expression in D. melanogaster expressed through elav-Gal4 and 
GawBl(3)31-1. 
 
H2.1 Climbing ability at 25°C 
 
 
Genotype Slope (k) Standard 
error 
95% 
Confidence 
interval 
R2 p-value Significant 
elav-Gal4; UAS-
lacZ 
0.06359 0.008349 0.04609 to 
0.08364 
0.6669 N/A N/A 
elav-Gal4; UAS-
Hippi-RNAi 
0.01175 0.001981 0.00779 to 
0.01578 
0.4311 <0.0001 Yes 
GawBl(3)31-1; UAS-
lacZ 
0.02342 0.002958 0.01751 to 
0.02934 
0.5906 N/A N/A 
GawBl(3)31-1; UAS-
Hippi-RNAi 
0.06288 0.00704 0.04871 to 
0.07705 
0.7202 <0.0001 Yes 
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Appendix I – Supplemental data for Figure 4.2  
 
 
Table I1. Statistical analysis of longevity between the UAS-lacZ control and altered Hippi 
expression in D. melanogaster expressed through Ddc-Gal4HL4.3D, Ddc-Gal4HL4.36 and 
Ddc-Gal4HL4.3D plus Ddc-Gal4HL4.36. 
 
I1.1 Longevity at 25°C 
 
Genotype Number of 
Flies (N) 
Median 
Survival 
(Days) 
p-value 
compared 
to control 
Significant 
ple-Gal4; UAS-lacZ    362 70 N/A N/A 
ple-Gal4; UAS-Hippi-
RNAi 
351 70 <0.0001 Yes 
Ddc-Gal4HL4.3D; UAS-lacZ 692 54 N/A N/A 
Ddc-Gal4HL4.3D; UAS-
Hippi-RNAi 
 
509 50 0.0016 Yes 
Ddc-Gal4HL4.36; UAS-lacZ 366 64 N/A N/A 
Ddc-Gal4HL4.36; UAS-
Hippi-RNAi 
352 68 0.0008 Yes 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-lacZ 
408 63 N/A N/A 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hippi-
RNAi 
208 58 0.0034 Yes 
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Table I2. Statistical analysis of locomotor ability between the UAS-lacZ control and 
altered Hip1 expression in D. melanogaster expressed through Ddc-Gal4HL4.3D, Ddc-
Gal4HL4.36 and Ddc-Gal4HL4.3D plus Ddc-Gal4HL4.36. 
 
I2.1 Climbing ability at 25°C 
 
Genotype Slope (k) Standard 
error 
95% 
Confidence 
interval 
R2 p-value Significant 
ple-Gal4; UAS-lacZ    0.07167 0.01303 0.0415 to 
0.1143 
0.4255 N/A N/A 
ple-Gal4; UAS-Hippi-
RNAi 
 
0.01924 0.004421 0.01039 to 
0.02809 
0.2312 <0.0001 Yes 
 
Ddc-Gal4 HL4.3D; UAS-
lacZ 
0.05996 0.01053 0.03851 to 
0.08142 
0.585 N/A N/A 
Ddc-Gal4 HL4.3D; UAS-
Hippi-RNAi 
0.05671 0.005361 0.04577 to 
0.06764 
0.7887 0.0025 Yes 
Ddc-Gal4HL4.36; UAS-lacZ 0.03101 0.005868 0.01921 to 
0.04280 
0.3459 N/A N/A 
 
Ddc-Gal4HL4.36; UAS-
Hippi-RNAi 
0.03139 0.002608 0.02616 to 
0.03662 
0.7756 <0.0001 Yes 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-lacZ 
0.05062 0.005911 0.03876 to 
0.06248 
0.7196 N/A N/A 
Ddc-Gal4HL4.3D; Ddc-
Gal4HL4.36; UAS-Hippi-
RNAi 
0.0267 0.006957 0.01251 to 
0.04089 
0.347 <0.0001 Yes 
 
 
